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Abstract We report results regarding the use of 1H-NMR
spectroscopy in the study of the conformational behaviour
and optical activity of omeprazole. Changes in the chem-
ical shifts of chosen atoms reveal that the conformational
behaviour of omeprazole is temperature and pH sensitive.
Separation and identification of omeprazole enantiomers
in the presence of natural and derivative cyclodextrins,
such as b-cyclodextrin (bCD) and methyl-b-cyclodextrin
(MbCD) are achieved using 1H-NMR spectroscopy, with
information from molecular dynamics simulation. This
work shows that bCD includes preferentially R-(–)-ome-
prazole, acting as a chiral selector. This discrimination of
omeprazole enantiomers by cyclodextrins allows develop-
ment of pharmaceutical formulations with a better
bioavailability profile.
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Introduction
Omeprazole is a proton pump inhibitor in gastric parietal
cells and has been widely used in the treatment of peptic
ulcer, reflux oesophagitis and Zollinger–Ellison syndrome
[1]. The molecular structure of omeprazole is composed of
a substituted pyridine ring linked to a benzimidazole by a
sulphoxide group [2]. Normally, this drug is a racemate
with a chiral center in the sulphoxide group (Fig. 1).
It was demonstrated that both enantiomers have the
same in vitro capacity to decrease gastric acid formation,
but stereoselective metabolism by cytochrome P450 2C19
(abbreviated CYP2C19) results in different plasma con-
centrations. The S-(–)-enantiomer of omeprazole is less
susceptible to small intestinal and hepatic metabolism than
the (R)-isomer, and therefore, the chiral drug achieves
between 70% and 90% higher steady-state serum concen-
tration than the racemic omeprazole [3].
Cyclodextrins are cyclic organic compounds obtained by
enzymatic transformation of starch. These compounds have
found many applications because of their ability to form
inclusion complexes with a large number of molecules [4–6].
Although their main applications are in pharmaceutical, cos-
metic, food and agrochemical industries, cyclodextrins have
also proven to be of great utility in analytical chemistry,
especially in providing separations of positional and optical
isomers [7–9]. One example is the use of cyclodextrins as
chiral selectors for separation of omeprazole enantiomers by
high performance liquid chromatography in plasma samples
and by capillary electrophoresis [10].
The present work reports on the importance of cyclo-
dextrins, namely bCD and MbCD, as chiral selectors and
the use of 1H-NMR spectroscopy and Molecular Dynamics
as tools for isomeric selectivity analysis in order to obtain
pharmaceutical formulations with better bioavailability.
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Experimental
Materials
Racemic omeprazole (OME) was kindly donated by
Belmac Laboratory, S.A. (Madrid, Spain). b-Cyclodextrin
(bCD, MW = 1135) and methyl-b-cyclodextrin (MbCD,
MW = 1190 and an average degree of substitution,
DS = 0.5) were kindly donated by Roquette (Lestrem,
France). Deuterium oxide (D2O; 99.97%) and NaOD were
purchased from Euriso-top (Peypin, France) and Sigma–
Aldrich (St. Louis, MO), respectively. All other reagents were
of the highest purity available from commercial sources.
Methods
NMR spectroscopy
1H-NMR spectra were recorded at 25 C, 35 C and 50 C
on a Varian Unity-500 MHz spectrometer using a 5 mm
broadband NMR probe and a simple pulse-acquire sequence
with solvent presaturation. Acquisition parameters consisted
of 24k points covering a sweep width of 8 kHz, a pulse width
of 18 ls, corresponding to a 90 degree rf pulse, and a total
repetition time of 15 s. Digital zero filling to 64k and a
0.5 Hz exponential were applied before Fourier transfor-
mation. The resonance at 4.681 ppm due to residual solvent
(HOD) was used as the internal reference. Samples were
prepared by dissolving an amount of free and complexed
omeprazole with cyclodextrins, previously prepared by the
lyophilized method [11], in D2O to achieve in an omeprazole
concentration of 3 mM in all samples.
The final pH was adjusted to 10.30 ± 0.10 so as to min-
imize the degradation of omeprazole and in some samples
the pH was adjusted to 7.55 and 12.04 in order to study the
influence of the pH in the omeprazole structural conforma-
tion. 1H-NMR variations in the chemical shifts (Dd) were
calculated according to Dd = d (complex) - d (free).
Simulation details
The Molecular Dynamics simulations were performed
using the GROMACS package [12] and employing the
GROMACS ffgmx force field [13].
Fig. 1 Chemical structures of omeprazole optical isomers: (a) R and (b) S enantiomers and (c) b-cyclodextrin
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The bCD structure was obtained from the HIC-Up
on-line database [14]. The initial structure of the omepra-
zole molecule was also produced as a pdb file. The
structures were then converted to GROMACS input files
(conformation and topology) using PRODRG [15]. The
deprotonated form of OME present in solutions with
pH = 10 [16, 17] was obtained by extracting the benz-
imidazole proton when running PRODRG and setting the
partial charges on the molecule according to the charge
distributions obtained from GAMESS [18] at the pm3
level, for the protonated and deprotonated forms. The
minimized energy structures obtained from GAMESS and
GROMACS in the gas phase for the protonated forms
presented differences in bond length smaller than 0.05 A˚.
In order to maintain the electroneutrality of the systems,
one sodium ion was introduced. The long range electro-
static interactions were handled by particle-mesh ewald
method [19]. The solvent was considered explicitly using
the SPC water model and an algorithm for rigid water
molecules [20]. The system was enclosed in a cell with an
approximate volume of 33 9 32 9 32 A˚3 and with peri-
odic boundary conditions. Each cell enclosed more than
1020 water molecules. The simulation was conducted in
the NPT ensemble at a constant temperature of 300 K with
coupling to an external bath [21].
An equilibration run of at least 0.5 ns was done previous
to the production trajectory runs, using a timestep of 1 fs,
without any constraints. The formation of the inclusion
complex is a result of the equilibration process and equil-
ibration was only considered to be completed upon
inclusion. The production runs were carried for 30 ns with
a timestep of 2.0 ps.
Results and discussion
NMR spectroscopy
One of the problems in obtaining a stable pharmaceutical
formulation with omeprazole is the fact that it degrades
very rapidly at acidic or neutral pH values. At pH = 10 the
molecule is in the deprotonated form, presenting a better
stability and larger solubility. The 1H-NMR spectra at
25 C and pH = 10.30 ± 0.10 of free omeprazole, ome-
prazole complexed with bCD and with MbCD are shown in
Fig. 2a–c, respectively.
The expansion of the 1H-NMR spectrum of the molecule
in the region of the methoxy (aii) and methyl (bii) groups at
pH = 10.30 C and 25 C, revealed that the peaks attrib-
uted to these groups were ‘‘split’’, as shown in Fig. 3, with
the appearance of a smaller peak at slightly smaller d
values for each resonance. These small peaks were not
detectable at pH = 7.55, and at pH = 12.04 appear at the
left side of the large peak. At pH = 12.04, these smaller
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Fig. 2 1H-NMR spectra of free OME (a); OME complexed with bCD (b); and with MbCD (c) at 25 C and pH = 10.30 ± 0.10
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peaks present a larger relative area (*25%) compared to
the relative area of the same peak visible at pH = 10.30
(*10%). It should also be noted that the effect is identical
in both sets of protons, located at different ends of the
molecule. This behaviour may be explained by a depen-
dence of the conformational stability on the pH as observed
for other molecules [22]. The difference in the values of d
for the large and smaller peaks at pH = 10.30 is probably
related to aromatic electronic ring currents caused by
opposite ring effects, which at some metastable confor-
mation may deprotect the above mentioned protons. By
changing the pH, another metastable conformation is
favoured, in this case having a protecting effect. At
pH = 10.30, the relative area and d of the peaks attributed
to the protons in the methyl (bii) group vary with tem-
perature, as described in Table 1.
When the temperature is increased from 25 C to 50 C,
the d for the largest peak of the methyl group (bii)
increases from d = 1.764–2.083 ppm, with a similar
change in the d of the smaller peak, and the signal relative
ratio of the smaller peak increases steadily from 19% at
25 C to 22% at 35 C and to 34% at 50 C. These
3.7 3.6 3.5 3.4 3.3 PPM 2.1 2.0 1.9 1.8 1.7 PPM
3.7 3.6 3.5 3.4 3.3 PPM 2.1 2.0 1.9 1.8 1.7 PPM
3.7 3.6 3.5 3.4 3.3 PPM 2.1 2.0 1.9 1.8 1.7 PPM
pH=7.55
pH=10.30
pH=12.04
spuorglyhteMspuorgyxohteM
#
#
#
Fig. 3 Expansion of the 1H-NMR spectrum of free OME for the regions of methoxy [(ai) and (aii)] and methyl groups [(bi) and (bii)] at different
pHs at 25 C
Table 1 Chemical shifts and relative signal areas for peak 1 and peak
2 at pH = 10.30 as function of temperature
Temperature
(C)
Chemical shifts
1 (ppm)
Chemical shifts
2 (ppm)
Signal relative
ratio (%)*
25 1.764 1.756 19
35 1.901 1.893 22
50 2.083 2.076 34
* Relative signal area = (peak area 2)/(peak area 2 + peak area 1)
348 J Incl Phenom Macrocycl Chem (2008) 62:345–351
123
alterations are consistent with a very dynamic behaviour of
the drug, since the alterations in both chemical shifts and
ratios of conformers imply a significant alteration in
conformation.
Figure 4 shows the expansion of the 1H-NMR spectrum
and the d of complexed omeprazole with bCD in the region
of the methyl group (bii). This figure shows, at 25 C, the
appearance of two sets of two peaks, each in the region of
the methyl group (bii). Each of these sets is very similar to
the respective protons in the absence of cyclodextrin. The
relative area of the small peak in each set (*31%) is,
however, quite different from the corresponding areas in
the absence of cyclodextrin at 25 C (*10%). The sepa-
ration between the two sets indicates the separation
between two different populations, which tend to merge as
the temperature is increased. At 50 C a significant
superposition of the resonances occurs.
Molecular Dynamics simulation
Molecular Dynamics studies of the inclusion of the isomers
into the cyclodextrin cavity show that there is a slightly
deeper inclusion of the R isomer inside the cavity, as vis-
ible in Fig. 5.
At the same time, it was observed that the S isomer
retains a larger conformational freedom when included in
the cavity. This is visible in the larger dispersion of values
in the distribution of distances between the oxygens in
groups (aii) to the hydrogens on the positions 2 and 3 of the
cyclodextrin rings, as presented in Fig. 6.
The different d values observed for the two sets of peaks
may therefore be explained by the different proximity
between the methoxy (bii) group and the oxygens in
positions 2 and 3 in the wider side of the cyclodextrin
cavity, as shown in Fig. 7. The separation of these sets of
peaks in the presence of the cyclodextrin thus results from
the action of the latter as a chiral selector. In this view,
each set of peaks may be attributed to a specific isomer.
Previous work [9] has shown that the S isomer forms less
stable complexes with cyclodextrin, in accordance with our
observation that this isomer is less deeply included in the
cavity. The assignment of the peaks can also be done
resorting to the molecular dynamics results. The results
presented in Fig. 7 show that there is a significant differ-
ence in the proximity between the hydrogens in the OME
and the oxygens in the wider entrance of the cyclodextrin,
which may have a counterpart in the protection/
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Fig. 4 Expansion of the 1H-NMR spectra and Dd for the methyl group [(bii)] of OME complexed with bCD as a function of temperature,
pH = 10.30 ± 0.10
Fig. 5 Distribution of distances for the oxygen in group (aii) and the
center of mass of each of the benzimidazole rings (com1 denotes
the center of mass of the ‘‘imidazole’’ part and com2 that of the
‘‘benzene’’ ring) to the center of mass of the group formed by O4 of
the cyclodextrin. Full line and dashed line correspond to isomers R
and S respectively
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deprotection of the former. Following this reasoning,
the set with larger d can be attributed to isomer R. The
tendency for overlap between the two sets of peaks as
temperature increases can be explained by an increased
conformational freedom of the two molecules that results
in a less specific interaction.
In the case of the drug complexed with MbCD, the
methylated derivative, the enantiomeric separation is less
marked and with increasing temperature the two enantio-
mers become almost indistinguishable. We suggest that this
observation results from the formation of a more stable
inclusion complex between this cyclodextrin and each of
the drug enantiomers [23], and that with increasing tem-
perature existing differences in binding constants tend to
disappear (smaller Dd).
The results observed indicate that in the presence of
cyclodextrin the drug shows enantioselectivity because
bCD acts as a chiral selector. However, this fact is not so
clearly observed in the presence of MbCD, probably
because in this case the inclusion of both enantiomers in
the cyclodextrin cavity is deeper [23].
Conclusion
This work allows concluding that the combined use of NMR
spectroscopy and molecular dynamics simulation consti-
tutes a clear, simple, and easy methodology to analyse the
occurrence of chiral selectivity for drugs, in this case OME,
in presence of natural and derivative cyclodextrins, bCD
and MbCD. The characteristic features in the spectra have
been rationalised resorting to information provided by the
Molecular Dynamics simulations, indicating that OME
(R)-isomer is preferentially included in the bCD cavity,
acting this cyclodextrin as a chiral selector for this com-
pound. The same was not observed in the presence of
MbCD, because with this cyclodextrin the inclusion of the
drug in the cavity is deeper, and this fact hampers the use of
this cyclodextrin as a chiral selector in the case of OME.
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